|
Warnex Inc
test for the v617f jak2 mutation Test For The V617f Jak2 Mutation, supplied by Warnex Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/jak2+mutation+testing/jak2+gene/pmc05682567-111-32-23 Average 90 stars, based on 1 article reviews
test for the v617f jak2 mutation - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
Ipsogen Inc
jak2 mutation testing kits Jak2 Mutation Testing Kits, supplied by Ipsogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/jak2+mutation+testing/jak2+mutaquant+kit/10__1309_slash_ajcplriojp55jayt-97-2-9 Average 90 stars, based on 1 article reviews
jak2 mutation testing kits - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
Quest Diagnostics
testing for jak2 various mutations ![]() Testing For Jak2 Various Mutations, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/jak2+mutation+testing/jak2+v617f+testing/pmc02921382-109-13-19 Average 90 stars, based on 1 article reviews
testing for jak2 various mutations - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
Quest Diagnostics
jak2 mutation testing ![]() Jak2 Mutation Testing, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/jak2+mutation+testing/jak2+v617f+testing/pmc02607565-40-8-5 Average 90 stars, based on 1 article reviews
jak2 mutation testing - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
Quest Diagnostics
plasma testing of jak2 mutations ![]() Plasma Testing Of Jak2 Mutations, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/jak2+mutation+testing/jak2+v617f+testing/pm18362222-19-37-33 Average 90 stars, based on 1 article reviews
plasma testing of jak2 mutations - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
Journal: PLoS ONE
Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
doi: 10.1371/journal.pone.0012165
Figure Lengend Snippet: Top, schematic diagram of the JAK2 protein showing JAK homology domains 1 through 7 (JH1-JH7) with the JH2 pseudokinase domain highlighted in black. The corresponding exon regions of the mRNA is shown with the exons 13, 14, and 15. Because exon 14 is consists of 88 bp, its deletion leads to frameshift and early termination of translation after coding for seven new amino acids and elimination of the V617 codon of JAK2 (lower panel). The resulting truncated JAK2 protein is shown on the bottom.
Article Snippet: A patent has been filed on finding by Quest Diagnostics and testing for
Techniques:
Journal: PLoS ONE
Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
doi: 10.1371/journal.pone.0012165
Figure Lengend Snippet: Upper panels: Detection of Δexon14 is relatively easy when the transcript is present at high levels (eg, 29% of total JAK2 transcript). Detection is more difficult when the Δexon14 transcript makes up a small proportion of total JAK2 transcript (eg, 6.9%). Normal control is shown on the bottom.
Article Snippet: A patent has been filed on finding by Quest Diagnostics and testing for
Techniques: Control
Journal: PLoS ONE
Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
doi: 10.1371/journal.pone.0012165
Figure Lengend Snippet: Prevalence and Relative Level of the ΔExon14 JAK2 Transcript in Patients with Suspected or Confirmed Myeloproliferative Neoplasms (MPNs)
Article Snippet: A patent has been filed on finding by Quest Diagnostics and testing for
Techniques:
Journal: PLoS ONE
Article Title: JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
doi: 10.1371/journal.pone.0012165
Figure Lengend Snippet: Lysates were prepared from the indicated human CML K562 cell line (Lane1), a patient with chronic myelogenous leukemia (lane 2), and 5 patients with chronic MPNs (Lanes 3–7). Patient 1: non-CML CMPD, JAK2 V617F positive; Patient 2: non-CML CMPD, JAK2 V617F negative; Patient 3: non-CML CMPD, JAK2 Δexon14 positive; Patient 4: non-CML CMPD, JAK2 Δexon14 positive; Patient 5: non-CML CMPD, JAK2 Δexon14 positive. Top Panel: Probing with an anti-JAK2 N-terminal clone yielded a wild-type JAK2 band at 130 kDa in the K562 and other negative control lanes, and an additional band at 75 kDa only in patients with expression of Δexon14 transcript. Bottom Panel: An anti-JAK2 clone directed against the carboxyl-terminus of JAK2 yielded only a single band at 130 kDa.
Article Snippet: A patent has been filed on finding by Quest Diagnostics and testing for
Techniques: Negative Control, Expressing
Journal: The Journal of Molecular Diagnostics : JMD
Article Title: Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias
doi: 10.2353/jmoldx.2009.080114
Figure Lengend Snippet: Table 1
Article Snippet: Peripheral blood samples sent to
Techniques: